A new test could reveal how radiation affects the liver

NCT ID NCT06899152

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This pilot study explores whether a combination of advanced MRI scans and a blood test called HepQuant DuO can measure liver function in people receiving radiation therapy for liver cancer. The study will enroll about 40 adults with liver cancer or liver metastases. The goal is to see if these tests are feasible and can detect changes in liver health before and after radiation, which could help guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HepQuant DuO diagnostic test and multiparametric MRI scans
What this could lead to
If successful, this could lead to a non-invasive way to monitor liver health during radiation therapy, potentially helping doctors tailor treatment to protect liver function.
What could go wrong
This is a small pilot study focused on feasibility, not effectiveness. The tests may not reliably reflect liver function or may not be practical in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.